Search for: "Pfizer, Inc., a Delaware Corporation"
Results 1 - 20
of 44
Sort by Relevance
|
Sort by Date
1 Feb 2023, 9:05 pm
Pfizer was a major contributor to the level of healthcare M&A, announcing a number of deals, including its $11.6 acquisition of Biohaven Pharmaceuticals, $5.4 billion acquisition of Global Blood Therapeutics and $525 million acquisition of ReViral. [read post]
3 Jan 2023, 1:47 pm
As discussed here (second item), in November 2022, the parties to the Delaware lawsuit announced that the case had settled for $33.75 million. [read post]
19 Apr 2022, 5:05 am
The Anti-Kickback Statute prohibits offering or accepting kickbacks intended to generate health care business. [read post]
10 Sep 2019, 8:03 pm
More recently, in Pfizer, Inc. v Arch Ins. [read post]
23 Aug 2019, 6:00 am
Pfizer Inc. v. [read post]
31 May 2019, 8:39 am
Pfizer, Inc., 2016 WL 4548101, at *5 (Del. [read post]
20 Sep 2016, 7:43 pm
Pfizer, Inc., C.A. [read post]
19 Feb 2016, 11:57 am
Asbestos Corporation Ltd, 2014 WL 9910834 (Ill. [read post]
15 Jul 2015, 4:30 am
Pfizer, Inc., 2015 WL 3999488 (E.D. [read post]
18 Jul 2014, 11:55 am
Pfizer, Inc., 716 F.3d 1087, 1092-93 (8th Cir. 2013). [read post]
2 Oct 2012, 1:08 pm
Pfizer Inc. [read post]
21 Jun 2012, 11:46 am
Pfizer, Inc.47. [read post]
18 Jun 2012, 2:00 am
Pfizer, Inc. v. [read post]
10 Nov 2011, 1:42 pm
Axcelis Technologies, Inc., 1 A.3d 281 (Del. 2010), the Delaware Supreme Court confirmed that the board has substantial discretion to do just that. [read post]
6 Jul 2011, 2:21 am
Biopet Vet Lab, Inc., et. al. [read post]
8 Apr 2011, 5:50 am
Nov. 22, 1988); Pfizer Inc. v. [read post]
12 Nov 2010, 12:58 pm
This afternoon we are lucky to be here with Justice Jacobs of the Delaware Supreme Court to discuss Important Developments in Delaware Corporate Law. [read post]
24 Aug 2010, 8:00 am
Axcelis Technologies, Inc., 2009 Del. [read post]
12 Aug 2010, 3:50 pm
Axcelis Technologies, Inc., No. 594, 2009 (Del. [read post]
20 Jul 2010, 3:41 pm
On July 14, 2010, the United States District Court for the Southern District of New York, in the case of In Re: Pfizer Inc. [read post]
